OA-02 Multiplex CRISPR/Cas9 Genome Editing of Cord Blood-derived CAR NK Cells to Improve Their Persistence and Antitumoral Potential Against Multiple Myeloma

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01843-3

Eva Castellano, Almudena García-Ortiz, Laura Ugalde, Elena Maroto-Martin, Jessica Encinas, Raquel Oliva, Laura García-García, Noemí Álvarez, Gonzalo Carreño, Rosa Ayala, Laura Córdoba, Alejandra Leivas, Guillermo Suñé, Rafael Alonso Fernández, Maria Teresa Cedena, Beatriz Martín-Antonio, Joaquín Martínez-Lopez, Paula Río, Antonio Valeri

引用次数: 0

查看原文本刊更多论文

OA-02 对脐带血 CAR NK 细胞进行多重 CRISPR/Cas9 基因组编辑，提高其持久性和抗多发性骨髓瘤的潜力

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.